PIKing the right patient.
Level V
Where this comes from
- Record sourced from PubMed, PMID 20538763.
- Also identified by DOI 10.1158/1078-0432.CCR-10-1201.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HER2 amplification and PIK3CA mutation were validated as biomarkers for sensitivity to the single-agent phosphoinositide 3-kinase (PI3K) inhibitor, GDC-0941, in breast cancer models. A novel expression profile was developed to identify other breast cancers sensitive to PI3K inhibitors. These expression studies highlighted feedback networks connecting TORC1, PI3K, and mitogen-activated protein kinase (MAPK) pathways, and underscored the potential for combination therapies.
Medical subject headings
- Breast Neoplasms
- Indazoles
- Phosphoinositide-3 Kinase Inhibitors
- Sulfonamides